MIF-1 (Melanostatin): The Complete Guide

MIF-1 (Melanocyte-stimulating hormone release-Inhibiting Factor 1) is the tripeptide Pro-Leu-Gly-NH₂ — three amino acids with a C-terminal amide. Also called Melanostatin or simply PLG.

Identity quirk — it is the oxytocin tail.

Oxytocin’s sequence is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2. The C-terminal tripeptide is Pro-Leu-Gly-NH₂ — that’s MIF-1. It can be enzymatically cleaved from oxytocin in vivo, which is part of how the molecule was originally identified.

Discovery (1971):

• PMID 4398196 — Nair RM, Kastin AJ, Schally AV. Biochem Biophys Res Commun 1971. Foundational identity paper.
• PMID 5283931 — Celis ME, Taleisnik S, Walter R. Proc Natl Acad Sci U S A 1971. Independent structure confirmation.
• Originally proposed as a hypothalamic factor inhibiting melanocyte-stimulating hormone release in amphibian models. The "human MSH-release inhibitor" framing is dated — modern interest is in central D2 receptor modulation.

Naming note:

"Melanostatin DM" is a name occasionally seen on vendor pages. The "DM" suffix appears in zero peer-reviewed primary-literature records — it is a vendor SKU code, not a chemical designator. Use "MIF-1," "Melanostatin," "Pro-Leu-Gly-NH₂," or "PLG" instead.

Regulatory status:

• FDA (US): never approved. No NDA, no IND on file. Sold as research chemical.
• EMA (EU): not approved.
• WADA 2026: not on the prohibited list by name. As an unapproved investigational substance, S0 (non-approved substances) catch-all may apply.

Modern mechanism: positive allosteric modulator of D2 dopamine receptors

The most rigorously characterized modern action of MIF-1 is as a positive allosteric modulator (PAM) of dopamine D2 receptors. This means MIF-1 doesn’t directly activate D2 itself — it binds an allosteric site that amplifies D2 activation by endogenous dopamine or by D2 agonists.

• Costa-Almeida et al. 2026 (PMID 41687543) characterized MIF-1 as a first-in-class ago-allosteric D2 PAM — the most recent verified primary literature.
• The allosteric mechanism is consistent with dose-response data showing biphasic effects (moderate doses better than high doses) — classic PAM behavior.
• This mechanism makes MIF-1 a candidate L-DOPA potentiator in Parkinson’s disease, since L-DOPA-derived dopamine acts on D2 and PAMs amplify that signal.

Original framing (1970s): MSH-release inhibition

Originally identified in amphibian skin-darkening assays as a factor that inhibited MSH release. The amphibian biology was real but the human relevance has been controversial since the 1970s. The "MSH-inhibitor" framing should not be the lead in modern human-use copy.

What MIF-1 is NOT:

• Not a direct D2 agonist. Allosteric only.
• Not a melanocortin agonist or antagonist. Despite the original "MSH-inhibitor" naming, it doesn’t act on the melanocortin receptors.
• Not an opioid agonist. See the opioid section below for an important encyclopedia-content correction.

The MIF-1 human-trial era was the late 1970s and 1980s, in two main indications: Parkinson’s disease and depression. Outcomes were mixed and small. No modern Phase 2/3 trial exists.

Parkinson’s disease — honest record:

Audit-correction: the existing StackTrax encyclopedia entry cites positive 1970s pilots while omitting a verified negative trial. Both directions need to be visible.

• Several small open-label Parkinson’s pilots in the 1970s reported some symptomatic improvement.
• Caraceni T & Parati EA 1979 — PMID 39308 — "Failure of MIF-I to affect behavioral responses in patients with Parkinson's disease under L-dopa therapy." This is the explicit negative trial that often gets omitted from positive-leaning summaries.
• Net read: signal possibly real, possibly placebo, definitely not robustly replicated. Modern PD therapeutics did not build on MIF-1.

Depression:

• Ehrensing RH & Kastin AJ 1978 — PMID 25588. Small placebo-controlled trial in depressed patients. Showed antidepressant signal at moderate doses, with biphasic dose-response — moderate doses worked better than high doses. This pattern is consistent with the modern D2-PAM mechanism.
• Implication: a "more is better" dosing framing is mechanistically wrong for MIF-1.
• No modern depression trial of MIF-1 has been conducted.

Opioid interaction — CRITICAL ENCYCLOPEDIA CORRECTION

The existing StackTrax encyclopedia entry claims MIF-1 "reduces opioid tolerance / attenuates withdrawal." This is wrong — that effect refers to a different molecule, cyclo(Leu-Gly).

The actual MIF-1 (Pro-Leu-Gly-NH₂) literature shows the OPPOSITE direction:

• MIF-1 antagonizes morphine analgesia in animal and human studies.
• PMID 6151672 documents this antagonism, including in humans.
• Cyclo(Leu-Gly) is a cyclic-dipeptide derivative with different pharmacology — it’s the cyclic-dipeptide work that produced the "reduces opioid tolerance" findings.

The encyclopedia conflated parent MIF-1 with cyclo(Leu-Gly). This guide corrects that.

• Half-life: very short. Pro-Leu-Gly-NH₂ is a tripeptide (~285 Da), unprotected by terminal modifications other than the C-terminal amide. Plasma half-life on the order of minutes in animal models.
• Routes used in published studies: oral, IV, intranasal, IM — all reported in 1970s/80s human trials.
• BBB penetration: reported in older literature based on CNS pharmacodynamic effects in animals. Quantitative human CSF / PET data not located.
• Bioavailability: not well-characterized; generally consistent with what would be expected for a small unmodified peptide.

Implication for dosing: the biphasic dose-response in depression (PMID 25588) means a higher dose is not necessarily a stronger dose. PAM behavior at the receptor level can produce inverted-U dose-response curves where over-dosing reduces effect.

StackTrax does not endorse MIF-1 use. No modern controlled trial. The dosing below reflects the historical 1970s/80s trial doses plus community convention.

Parameter	Range
Dose (intranasal, community)	50–200 µg/day, often split AM/PM
Dose (SC, less common)	50–200 µg/day
Cycle length	2–6 weeks (community); historical depression trials were 4–6 weeks
Route	Intranasal most common; SC less common; oral has poor characterization

Dose-response caveat: moderate doses outperformed high doses in the only positive depression trial (Ehrensing & Kastin 1978). "More is better" is mechanistically wrong for MIF-1.

From the 1970s/80s human trials and limited modern community reports:

• Generally well tolerated in the small published trials.
• Headache occasionally reported (community).
• Mild GI effects with oral dosing.
• Nasal irritation with intranasal route.
• No distinctive serious adverse-event pattern in published trials.

Theoretical concerns (none validated in long-term human use):

• D2 PAM activity theoretically could exacerbate psychotic symptoms in vulnerable individuals (D2 dopamine signaling is amplified).
• Antagonism of opioid analgesia — if you’re using opioids for pain, MIF-1 may reduce their effect (PMID 6151672).
• No published carcinogenicity, reproductive toxicity, or chronic-use safety data.
• No Western pharmacovigilance database (FAERS, EudraVigilance) data — never approved.

• Pregnancy / breastfeeding — not studied; default contraindication.
• Active or prior psychotic disorder (schizophrenia, schizoaffective disorder) — theoretical D2 PAM concern.
• Active opioid analgesic use — MIF-1 may antagonize opioid analgesia (PMID 6151672); coordinate with prescriber.
• Concurrent dopamine agonists (PD medications including L-DOPA, pramipexole, ropinirole) — theoretically additive D2 effects; physician supervision required.
• Concurrent dopamine antagonists (typical/atypical antipsychotics, metoclopramide) — theoretical interference.
• Severe Parkinson’s disease — the trial record is mixed; not a substitute for established PD therapy.
• Athletes subject to anti-doping testing — consult your governing body. WADA S0 catch-all may apply.

Compound	Mechanism / nature	Difference from MIF-1
Oxytocin	Full 9-aa neuropeptide	MIF-1 is the C-terminal tripeptide of oxytocin (Pro-Leu-Gly-NH2). Different molecule, different mechanism (oxytocin acts on the OXTR; MIF-1 acts as a D2 PAM).
Cyclo(Leu-Gly)	Cyclic dipeptide derivative	Different molecule. The "reduces opioid tolerance" claim that some sources attach to MIF-1 actually refers to cyclo(Leu-Gly). MIF-1 itself antagonizes opioid analgesia (PMID 6151672).
TRH (Thyrotropin-Releasing Hormone)	Tripeptide pGlu-His-Pro-NH2	Different sequence; different target (TSH/PRL release vs D2 modulation).
α-MSH and melanocortin agonists (PT-141, MT-2, MT-1)	Melanocortin receptor agonists	Despite MIF-1’s original "MSH-inhibitor" naming, it does not act on melanocortin receptors at relevant concentrations. Direction of effect is also different (modulation vs agonism).
Semax	ACTH(4–7) analog with Pro-Gly-Pro cap	Different sequence, different target (BDNF/NGF upregulation). Both small synthetic peptides with central effects but mechanistically distinct.
Selank	Tuftsin analog	Different sequence, GABAergic anxiolytic mechanism.
L-DOPA / levodopa	Dopamine precursor (FDA-approved PD drug)	L-DOPA increases dopamine availability; MIF-1 amplifies the response to existing dopamine via D2 PAM. Mechanistically complementary but not equivalent. MIF-1 is not a substitute for L-DOPA.
D2 agonists (pramipexole, ropinirole)	Direct D2 agonists	MIF-1 is allosteric only; doesn’t directly activate D2.